Get the Stockscreener App
1.13
40.72%
0.327
After Hours:
1.15
0.02
+1.77%
Aspire Biopharma Holdings Inc stock is traded at $1.13, with a volume of 7.35M.
It is up +40.72% in the last 24 hours and down -20.98% over the past month.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
See More
Previous Close:
$0.803
Open:
$0.833
24h Volume:
7.35M
Relative Volume:
7.23
Market Cap:
$5.68M
Revenue:
-
Net Income/Loss:
$-28.70M
P/E Ratio:
-0.0228
EPS:
-49.5275
Net Cash Flow:
$-3.22M
1W Performance:
+61.61%
1M Performance:
-20.98%
6M Performance:
-92.53%
1Y Performance:
-95.59%
1-Day Range:
$0.833
$1.29
1-Week Range:
$0.5483
$1.29
52-Week Range:
$0.5483
$35.01
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Name
Aspire Biopharma Holdings Inc
Sector
Industry
Phone
561-704-8527
Address
23150 FASHION DRIVE, SUITE 232, ESTERO
Compare ASBP vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
1.13 | 4.03M | 0 | -28.70M | -3.22M | -49.53 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Aspire Biopharma Holdings Inc Stock (ASBP) Latest News
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
ASBP Soars: Biotech Turbulence Fuels an Unexpected 17% Jump - Bitget
Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack - Livingston Daily
Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion - Black Hills Pioneer
ASBP Technical Analysis | Trend, Signals & Chart Patterns | ASPIRE BIOPHARMA HOLDINGS IN (NASDAQ:ASBP) - ChartMill
Aspire Biopharma Plunges 19.5% on Intraday Freefall: What’s Fueling the Sharp Drop? - Bitget
Aspire subsidiary names John Choe as western sales director By Investing.com - Investing.com South Africa
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution - Record Searchlight
Aspire subsidiary names John Choe as western sales director - Investing.com
Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director - ACCESS Newswire
He drove 70% sales growth at Yerbaé — now Buzz Bomb hires him - Stock Titan
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - The Gardner News
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity - Erie Times-News
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit - The Hutchinson News
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026 - Black Hills Pioneer
Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with N - GuruFocus
Aspire Biopharma Holdings Inc Stock (ASBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):